Taurine helps oligodendrocytes, which are cells responsible for myelin production, to fully mature and activate the remyelination process of damaged nerve cells.
The findings were reported in the study, “Metabolomics-based discovery of a metabolite that enhances oligodendrocyte maturation,” published in the journal Nature Chemical Biology.
“Remission of MS symptoms is dependent on the process of remyelination, so using taurine in combination with an existing MS drug and a future remyelination-inducing treatment may help patients by improving overall efficacy,” Luke Lairson, PhD, the study’s co-lead author, said in a press release.
“This could be something to add to an MS therapeutic regime,” added Lairson, an assistant professor of chemistry at The Scripps Research Institute (TSRI).
In a previous study published in the journal Nature, researchers found that Cogentin (benztropine) – a U.S. Food and Drug Administration-approved therapy for Parkinson’s disease – may also benefit MS patients.